Report Overview

The European Oncology Therapeutics market is expected to exhibit a CAGR of approximately 6.3% during the forecast period.

Cancer in Sweden is responsible for nearly 26% of the mortalities that occur due to Non-Communicable diseases. According to the Global Cancer Observatory, the number of new incident cancer cases for the year 2018 was 4.2 million and the deaths exceeded 1.94 million in Europe. This offers an exciting and dynamic environment for market growth in the coming years. Prostate cancer is the fourth most common cause of death after Coronary heart disease, Alzheimers Stroke, followed by Lung Cancer. The cancer diagnostics market is on the verge of explosion with the incidence of new cancer cases on the rise. This provides a huge market opportunity for the development of new drugs and technologies which will best benefit the population under scrutiny.



Market Drivers

Oncology Therapeutics market in Sweden is mainly driven by the increase in incidence of new cancer cases in the country along with a rise in their prevalence.

The Sweden Government warrants for an increased per capita spending on healthcare. This is one of the most promising drivers of the market. Along with this, there has been increased funding for the field of research and development in this area owing to the grave scenario of the disease.

A general increase in awareness regarding the oncological conditions and their complications have paved the way for timely diagnosis and care which in turn drive the drug market.